Novo Nordisk

News

Encouraging early sales data for oral Wegovy has buoyed Novo Nordisk, as Lilly waits for an FDA decision on its rival orforglipron, now due in Q2.

News

Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.

News

Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.

News

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide.

News

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.

News

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.